[go: up one dir, main page]

WO2024063740A3 - Triazole and hydrazide-hydrazone derivative hybrid molecules with antitumoral effect and the synthesis methods of these molecules - Google Patents

Triazole and hydrazide-hydrazone derivative hybrid molecules with antitumoral effect and the synthesis methods of these molecules Download PDF

Info

Publication number
WO2024063740A3
WO2024063740A3 PCT/TR2023/050991 TR2023050991W WO2024063740A3 WO 2024063740 A3 WO2024063740 A3 WO 2024063740A3 TR 2023050991 W TR2023050991 W TR 2023050991W WO 2024063740 A3 WO2024063740 A3 WO 2024063740A3
Authority
WO
WIPO (PCT)
Prior art keywords
molecules
hydrazide
synthesis methods
triazole
hydrazone derivative
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/TR2023/050991
Other languages
French (fr)
Other versions
WO2024063740A2 (en
Inventor
Nuray GUZELDEMIRCI
Ebru Didem COSAR
Sevde Nur BILTEKIN KALELI
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bezmialem Vakif Universitesi
Istanbul Medipol Universitesi
Istanbul Universitesi Rektorlugu
Original Assignee
Bezmialem Vakif Universitesi
Istanbul Medipol Universitesi
Istanbul Universitesi Rektorlugu
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from TR2022/014442 external-priority patent/TR2022014442A2/en
Application filed by Bezmialem Vakif Universitesi, Istanbul Medipol Universitesi, Istanbul Universitesi Rektorlugu filed Critical Bezmialem Vakif Universitesi
Priority to EP23868731.3A priority Critical patent/EP4590299A2/en
Publication of WO2024063740A2 publication Critical patent/WO2024063740A2/en
Publication of WO2024063740A3 publication Critical patent/WO2024063740A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention relates to hydrazide and hydrazide-hydrazone derivative molecules with antitumoral effect, bearing 1,2,4-triazole rings, which are effective on the MCF-7 breast cancer cell line and on cyclooxygenase-1 (COX-1 ), especially having a selective inhibition activity on the cyclooxygenase-2 (COX-2) enzyme, and synthesis methods of these molecules. The general structure of the molecules of the invention is shown by Formula (X).
PCT/TR2023/050991 2022-09-20 2023-09-20 Triazole and hydrazide-hydrazone derivative hybrid molecules with antitumoral effect and the synthesis methods of these molecules Ceased WO2024063740A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP23868731.3A EP4590299A2 (en) 2022-09-20 2023-09-20 Triazole and hydrazide-hydrazone derivative hybrid molecules with antitumoral effect and the synthesis methods of these molecules

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
TR2022/014442 TR2022014442A2 (en) 2022-09-20 Antitumoral effective triazole and hydrazide-hydrazone derivative hybrid molecules and synthesis methods of these molecules.
TR2022014442 2022-09-20

Publications (2)

Publication Number Publication Date
WO2024063740A2 WO2024063740A2 (en) 2024-03-28
WO2024063740A3 true WO2024063740A3 (en) 2024-05-02

Family

ID=90454882

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/TR2023/050991 Ceased WO2024063740A2 (en) 2022-09-20 2023-09-20 Triazole and hydrazide-hydrazone derivative hybrid molecules with antitumoral effect and the synthesis methods of these molecules

Country Status (2)

Country Link
EP (1) EP4590299A2 (en)
WO (1) WO2024063740A2 (en)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007047394A2 (en) * 2005-10-13 2007-04-26 Epix Delaware, Inc. Thiotriazolyl derivatives

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007047394A2 (en) * 2005-10-13 2007-04-26 Epix Delaware, Inc. Thiotriazolyl derivatives

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
ARMEN S. GALSTYAN: "Synthesis, Study of the Biological Activity of New 1,2,4‐Triazole Derivatives and Characteristics of the Relationship of the Structure and Biological Activity in a Series of the Latter", CHEMISTRYSELECT, WILEY - V C H VERLAG GMBH & CO. KGAA, DE, vol. 4, no. 42, 15 November 2019 (2019-11-15), DE , pages 12386 - 12390, XP093166796, ISSN: 2365-6549, DOI: 10.1002/slct.201902761 *
EFE DOĞUKAN DINCEL: "Design, synthesis, characterization and antimicrobial evaluation of some novel hydrazinecarbothioamide, 4‐thiazolidinone and 1,2,4‐triazole‐3‐thione derivatives", JOURNAL OF HETEROCYCLIC CHEMISTRY, WILEY-BLACKWELL PUBLISHING, INC., US, vol. 58, no. 1, 1 January 2021 (2021-01-01), US , pages 195 - 205, XP093166795, ISSN: 0022-152X, DOI: 10.1002/jhet.4159 *
HOVSEPYAN, T. R. ET AL.: "1, 2, 4-Triazole-Based Hybrid Heterocyclic Carbaldehyde Hydrazones and Their Effect on DNA Methylation Level", RUSSIAN JOURNAL OF ORGANIC CHEMISTRY, vol. 56, 2020, pages 2137 - 2142, XP037354458, DOI: 10.1134/S1070428020120143 *
SAMVELYAN, M. A. ET AL.: "Alkylation of 1, 2, 4-triazole-3-thiols with haloalkanoic acid ester s", RUSSIAN JOURNAL OF ORGANIC CHEMISTRY, vol. 53, 2017, pages 935 - 940, XP036283788, DOI: 10.1134/S1070428017060203 *

Also Published As

Publication number Publication date
WO2024063740A2 (en) 2024-03-28
EP4590299A2 (en) 2025-07-30

Similar Documents

Publication Publication Date Title
Liu et al. Byproduct promoted regioselective sulfenylation of indoles with sulfinic acids
Rezaei et al. Design, synthesis, and antifungal activity of triazole and benzotriazole derivatives
Backes et al. Synthesis and antifungal activity of substituted salicylaldehyde hydrazones, hydrazides and sulfohydrazides
Haider et al. 1, 3, 4-Thiadiazoles: A potent multi targeted pharmacological scaffold
Chimenti et al. Synthesis and in vitro selective anti-Helicobacter pylori activity of pyrazoline derivatives
Zhang et al. A catalyst-free approach to 3-thiocyanato-4H-chromen-4-ones
Li et al. Chemical ecogenomics-guided discovery of phytotoxic α-pyrones from the fungal wheat pathogen Parastagonospora nodorum
Bhalkar et al. Camptothecine production by mixed fermentation of two endophytic fungi from Nothapodytes nimmoniana
Zhu et al. Discovery of a new biphenyl derivative by epigenetic manipulation of marine-derived fungus Aspergillus versicolor
Chen et al. New bactericide derived from Isatin for treating oilfield reinjection water
Kommagalla et al. Optimization of the anti-cancer activity of the phosphatidylinositol-3 kinase pathway inhibitor PITENIN-1: switching thiourea with 1, 2, 3-triazole
Nihashi et al. Phytotoxic sesterterpene, 11-epiterpestacin, from Bipolaris sorokiniana NSDR-011
WO2024063740A3 (en) Triazole and hydrazide-hydrazone derivative hybrid molecules with antitumoral effect and the synthesis methods of these molecules
Seršen et al. Organoruthenium (II) complexes of acetazolamide potently inhibit human carbonic anhydrase isoforms I, II, IX and XII
Dong et al. Total Synthesis of Diverse Tetramic Acid Bearing cis‐Decalin Natural Products
Sapnakumari et al. Multicomponent synthesis, biological evaluation and molecular docking of new spiro-oxindole derivatives
Wang et al. Secondary metabolites produced by the deep-sea-derived fungus Engyodontium album
Misko et al. Structure-guided design of anti-cancer ribonucleotide reductase inhibitors
Williams et al. Genetic and chemical characterisation of the cornexistin pathway provides further insight into maleidride biosynthesis
Pan et al. Marine fungi as a goldmine for novel antibiotics: a 2024 perspective
Li et al. Synthesis and production of the antitumor polyketide aurovertins and structurally related compounds
Liu et al. Wortmannilactones I–L, new NADH-fumarate reductase inhibitors, induced by adding suberoylanilide hydroxamic acid to the culture medium of Talaromyces wortmannii
Zhao et al. Activation of the FOXM1/ASF1B/PRDX3 axis confers hyperproliferative and antioxidative stress reactivity to gastric cancer
Yu et al. Molecular docking, design, synthesis and antifungal activity study of novel triazole derivatives containing the 1, 2, 3-triazole group
Chen et al. Total synthesis of (±)-Lingzhilactone B via semipinacol rearrangement

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 23868731

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2023868731

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2023868731

Country of ref document: EP

Effective date: 20250422

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 23868731

Country of ref document: EP

Kind code of ref document: A2

WWP Wipo information: published in national office

Ref document number: 2023868731

Country of ref document: EP